利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.023 秒)

    MONOLITHIC DRUG DELIVERY SYSTEM
    3.
    发明申请
    MONOLITHIC DRUG DELIVERY SYSTEM 审中-公开
    单体药物递送系统

    公开(公告)号：US20140148495A1

    公开(公告)日：2014-05-29

    申请号：US14057786

    申请日：2013-10-18

    申请人： University of the Witwatersrand, Johannesburg

    发明人： Sibongile Ruth Sibambo ,  Viness Pillay ,  Yahya Essop Choonara

    IPC分类号： A61K9/00

    CPC分类号： A61K9/2009 ,  A61K9/0024 ,  A61K9/204

    摘要： An improved monolithic drug delivery dosage form releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relaxes on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate.

    摘要翻译： 改进的整体药物递送剂型以预定的速率释放药物活性剂。 该剂型包含盐析或交联的聚合物和药物活性剂。 盐析或交联的聚合物用于使药物活性剂聚合缠结，但是在使用中与水性介质接触时逐渐松弛，以预定的速率释放药物活性剂。

    Biodegradable implant
    4.
    发明授权
    Biodegradable implant 有权

    公开(公告)号：US10478527B2

    公开(公告)日：2019-11-19

    申请号：US15757475

    申请日：2016-09-05

    申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

    发明人： Viness Pillay ,  Yahya Essop Choonara ,  Pradeep Kumar ,  Lisa Claire Du Toit ,  Poornima Ramburrun

    IPC分类号： A61L27/48 ,  A61L27/16 ,  A61L27/20 ,  A61L27/52 ,  A61L27/54 ,  A61L27/58 ,  A61L27/56

    摘要： This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.

    Pharmaceutical dosage form
    7.
    发明授权
    Pharmaceutical dosage form 有权
    药物剂型

    公开(公告)号：US09439863B2

    公开(公告)日：2016-09-13

    申请号：US14376907

    申请日：2013-02-08

    申请人： University of the Witwatersrand, Johannesburg

    发明人： Viness Pillay ,  Yahya Essop Choonara ,  Felix Mashingaidse ,  Pradeep Kumar

    IPC分类号： A61K9/16 ,  A61K31/7072 ,  A61K9/50 ,  A61K9/00 ,  A61K9/20

    CPC分类号： A61K9/1652 ,  A61K9/0034 ,  A61K9/1647 ,  A61K9/1658 ,  A61K9/2077 ,  A61K9/5031 ,  A61K31/7072

    摘要： This invention relates to pharmaceutical dosage forms, particularly to pH dependent pharmaceutical dosage forms with enhanced and/or prolonged distribution of a pharmaceutical compound at a target site. More specifically, this invention relates to a controlled release intravaginal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which comprises microspheres encapsulated and/or embedded within a bioerodible polymeric matrix, together the microspheres and the matrix are formed into a caplet and/or tablet.

    摘要翻译： 本发明涉及药物剂型，特别是涉及具有药物化合物在靶位点的增强和/或延长分布的pH依赖性药物剂型。 更具体地，本发明涉及控释型阴道内药物剂型，更具体地涉及药物剂型，其包含包封和/或嵌入生物可腐蚀的聚合物基质内的微球，所述微球和所述基质一起形成囊片和 /或平板电脑。

    ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM
    8.
    发明申请
    ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM 审中-公开
    ORAMUCOSAL PHARMACEUTICAL剂型

    公开(公告)号：US20130252916A1

    公开(公告)日：2013-09-26

    申请号：US13736176

    申请日：2013-01-08

    申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

    发明人： Rupal Patel ,  Viness Pillay ,  Michael Paul Danckwerts

    IPC分类号： A61K9/00 ,  A61K47/38

    CPC分类号： A61K9/0056 ,  A61K9/0002 ,  A61K9/006 ,  A61K9/2054 ,  A61K9/2095 ,  A61K47/38

    摘要： This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation.

    摘要翻译： 本发明涉及以晶片形式的粘膜下药物剂型。 该晶片包括多孔，吸湿性粘膜粘合的聚合物基质，其中加入至少一种所需的药物活性化合物。 聚合物选自许多具有不同溶解速率的聚合物，并且在使用时口服时，基质粘附到粘膜表面以在预定的时间内溶解以释放药学活性化合物。 本发明还延伸到一种以晶片形式制造粘膜下药物剂型的方法，其包括冷冻干燥或冻干。